News Lilly beats Novo to China with an oral GLP-1 for obesity Lilly's orforglipron has been approved in China, becoming the first oral GLP-1 agonist to enter the Chinese weight management market.
News Third Rock in $2bn drug-hunting pact with China's Funnel New Chinese biotech Funnel has signed a $2bn-plus partnership with Third Rock Ventures, focused on using its AI platform to discover novel biologics.
News Bayer's Hyrnuo moves first-line for lung cancer in China Bayer's oral HER2 inhibitor Hyrnuo has been approved in China as a frontline therapy for advanced, HER2-mutant non-small cell lung cancer.
News Bayer gets first approval for stroke drug asundexian Bayer's oral Factor XIa inhibitor asundexian has been cleared in its first market, China, for secindary stroke prevention.
News US Treasury proposes curbs on Chinese biotech deals China has emerged as a major source of drug candidates for pharma groups, but a new proposal by the US Treasury could slam the brakes on future deals.
Market Access Is the next generation of Chinese biotech ready to go global... Will Chinese biotechs continue to transfer most ex-China rights, or retain their strongest assets and compete internationally themselves?
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.